Genetic Technologies Limited Price Chart
Genetic Technologies Limited GTG.XA Financial and Trading Overview
Genetic Technologies Limited stock price | 0.17 AUD |
Previous Close | 0.003 AUD |
Open | 0.003 AUD |
Bid | 0.002 AUD x N/A |
Ask | 0.003 AUD x N/A |
Day's Range | 0.003 - 0.003 AUD |
52 Week Range | 0.0025 - 0.009 AUD |
Volume | 1.37M AUD |
Avg. Volume | 2.56M AUD |
Market Cap | N/A |
Beta (5Y Monthly) | 0.560153 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.001 AUD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
GTG.XA Valuation Measures
Enterprise Value | 18.65M AUD |
Trailing P/E | N/A |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | N/A |
Price/Book (mrq) | 3 |
Enterprise Value/Revenue | 1.736 |
Enterprise Value/EBITDA | -2.156 |
Trading Information
Genetic Technologies Limited Stock Price History
Beta (5Y Monthly) | 0.560153 |
52-Week Change | -14.28% |
S&P500 52-Week Change | 20.43% |
52 Week High | 0.009 AUD |
52 Week Low | 0.0025 AUD |
50-Day Moving Average | 0.00302 AUD |
200-Day Moving Average | 0.0033875 AUD |
GTG.XA Share Statistics
Avg. Volume (3 month) | 2.56M AUD |
Avg. Daily Volume (10-Days) | 789.96K AUD |
Shares Outstanding | N/A |
Float | 7.85B |
Short Ratio | N/A |
% Held by Insiders | 9.45% |
% Held by Institutions | 0% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | N/A |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | June 30, 2022 |
Most Recent Quarter (mrq) | December 31, 2022 |
Next Fiscal Year End | June 30, 2023 |
Profitability
Profit Margin | -81.088% |
Operating Margin (ttm) | -84.19% |
Gross Margin | 62.45% |
EBITDA Margin | -80.53% |
Management Effectiveness
Return on Assets (ttm) | -29.56% |
Return on Equity (ttm) | -57.15% |
Income Statement
Revenue (ttm) | 10.74M AUD |
Revenue Per Share (ttm) | 0.001 AUD |
Quarterly Revenue Growth (yoy) | 44.10% |
Gross Profit (ttm) | 6.2M AUD |
EBITDA | -8650729 AUD |
Net Income Avi to Common (ttm) | -8709925 AUD |
Diluted EPS (ttm) | -0.001 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 5.05M AUD |
Total Cash Per Share (mrq) | 0.001 AUD |
Total Debt (mrq) | 612.39K AUD |
Total Debt/Equity (mrq) | 5.55 AUD |
Current Ratio (mrq) | 2.08 |
Book Value Per Share (mrq) | 0.001 |
Cash Flow Statement
Operating Cash Flow (ttm) | -7654500 AUD |
Levered Free Cash Flow (ttm) | -3807009 AUD |
Profile of Genetic Technologies Limited
Country | Australia |
State | VIC |
City | Fitzroy |
Address | 60-66 Hanover Street |
ZIP | 3065 |
Phone | 61 3 8412 7000 |
Website | https://genetype.com |
Industry | |
Sector(s) | |
Full Time Employees | 52 |
Genetic Technologies Limited, a molecular diagnostics company, provides predictive genetic testing and risk assessment tools to help physicians manage people's health in the United States, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. It operates in two segments, EasyDNA and GeneType/Corporate. The company offers BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, the company offers various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer brand names; and develops other risk assessment tests across a range of diseases, which include colorectal cancer, ovarian cancer, prostate cancer, coronary artery, and type 2 diabetes. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne, Translational Genomics Research Institute, Memorial Sloan Kettering New York Cambridge University, the Ohio State University, and Shivom. Genetic Technologies Limited was incorporated in 1987 and is headquartered in Fitzroy, Australia.
Q&A For Genetic Technologies Limited Stock
What is a current GTG.XA stock price?
Genetic Technologies Limited GTG.XA stock price today per share is 0.17 AUD.
How to purchase Genetic Technologies Limited stock?
You can buy GTG.XA shares on the Cboe AU exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Genetic Technologies Limited?
The stock symbol or ticker of Genetic Technologies Limited is GTG.XA.
How many shares does Genetic Technologies Limited have in circulation?
The max supply of Genetic Technologies Limited shares is 0.
What is Genetic Technologies Limited Price to Earnings Ratio (PE Ratio)?
Genetic Technologies Limited PE Ratio is now.
What was Genetic Technologies Limited earnings per share over the trailing 12 months (TTM)?
Genetic Technologies Limited EPS is -0.001 AUD over the trailing 12 months.